Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
about
Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Cost-effectiveness Analysis of ...... arcinoma of the Head and Neck.
@en
Cost-effectiveness Analysis of ...... arcinoma of the Head and Neck.
@nl
type
label
Cost-effectiveness Analysis of ...... arcinoma of the Head and Neck.
@en
Cost-effectiveness Analysis of ...... arcinoma of the Head and Neck.
@nl
prefLabel
Cost-effectiveness Analysis of ...... arcinoma of the Head and Neck.
@en
Cost-effectiveness Analysis of ...... arcinoma of the Head and Neck.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness Analysis of ...... arcinoma of the Head and Neck.
@en
P2093
Assuntina G Sacco
James D Murphy
Kate T Carroll
Kathryn R Tringale
Kaveh Zakeri
Linda Barnachea
P2860
P356
10.1093/JNCI/DJX226
P407
P577
2017-11-03T00:00:00Z